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ABSTRACT
Apoptosis, or programmed cell death, plays in important role in proliferative
disorders, particularly cancer. A decrease in apoptosis allows cancer cells to grow out of
control. These conditions make the apoptosis pathway an attractive target for new
strategies in cancer therapy. The purpose of this research project was to investigate the
anticancer potential of two compounds that occur naturally in common plants. All our
experiments utilize fluorescent molecular probes measured in a fluorescent microplate
reader or with a fluorescent microscope equipped for high-resolution, real-time, digital
imaging. Using human MCF-7 breast cancer cells, two compounds were tested for their
anticancer potential by measuring growth inhibition and apoptosis. Cucurbitacin E, a
triterpene sterol found in various plants, has exhibited concentration-dependent growth
inhibition due to cytotoxic cell death and apoptosis. The second compound, genistein, is
one of the primary isoflavones found in soy. A diet high in soy products, like those of
many Asian countries, has been shown to reduce the risk of breast cancer. We
demonstrated that treatment with genistein resulted in concentration dependent growth
inhibition with an effective concentration of 85|xM. Cells treated with genistein also
exhibited significant amounts of apoptosis, as determined by DNAfragmentation and
morphological characteristics. Total methanol extracts of soy, obtained from different
geographical locations, were assayed in the same manner. We found that these extracts
were also capable of growth inhibition and that the extent of these effects varied between
the extracts. The results presented support our conclusion that cucurbitacin E is highly
cytotoxic and may not be suitable for targeting the apoptosis pathway, while genistein
induces significant amounts of apoptosis by an unknown mechanism.
INTRODUCTION
Cells undergo the process of apoptosis, or programmed cell death, for various
reasons. For example, apoptosis naturally occurs when cells are infected by viruses, or
suffer irreparable damage. When cells of the body are enabled to bypass the apoptosis
pathway, serious consequences result manifested in proliferative disorders, particularly
cancer. A decrease in apoptosis allows cancer cells to grow out of control, resulting in
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tumor formation. If the apoptosis pathway could be restored, transformed cells could be
eliminated without inflammatory response or nonspecific drug interactions damaging
adjacent normal tissue. These conditions make the apoptosis pathway an attractive target
for new strategies in cancer therapy.
Development of cancer has not only been linked to genetic factors, but also
environmental factors and personal habits, like exercise and diet. In Asian countries
there are significantly fewer deaths from breast cancer in comparison to the United States
and Western Europe. Various studies done over the past 20 years have shown a clear
correlation between different lifestyles and the incidence of breast cancer, rather than
genetics in these populations. In particular, individuals in these Asian countries consume
20-50 times more soy products in comparison to Americans (1, 2). Genistein (4',5,7-
trihydroxyisoflavone), one of the primary isoflavonoids found in soy, has been shown to
inhibit protein tyrosine kinase (3, 4) and inhibit growth of various carcinoma cell lines
(1, 4, 5).
Cucurbitacins are triterpenes found in many plants that are believed to have medicinal
properties. In particular, cucurbitacin E is also been shown to be cytotoxic in prostate
carcinoma cells and is proposed to work by disrupting the F-actin cytoskeleton (6).
The question in our study was whether either of these compounds used apoptosis as
a mechanism of cell growth inhibition. To answer this question, we treated MCF-7 breast
carcinoma cells with the two compounds and determined the effective concentration
resulting in growth inhibition of 50% of the control (EC50).We determined the presence
of apoptosis by measuring DNA fragmentation and morphological criteria. Our findings
demonstrate that cucurbitacin E is highly cytotoxic, but does not induce apoptosis above
base line level. Therefore, we concluded that it may not be suitable for further study as
an anticancer agent. Genistein exhibited growth inhibition, along with significant
amounts of apoptosis making it a suitable candidate for further testing. The soy extracts




Cucurbitacin E and soy total methanol extracts were obtained from F. Halaweish
(South Dakota State University). Genistein was purchased from Sigma Chemical (St.
Louis, MO). Cell culture media and supplements were purchased from GIBCO. APO-
BrdU TUNEL Assay Kit and Hoescht 33342 were obtained from Molecular Probes.
Cell Culture
MCF-7 breast carcinoma cells were obtained from American Type Culture
Collection (Manassas, VA). The cells are cultured in RPMI-I640 media supplemented
with 10% fetal calf serum, 100 units/ml penicillin, 100p,g/ml streptomycin, and at 37° C
in a humidified incubator with 5% CO2. Growth inhibition assays were performed on
96-well plates (Falcon). Cells were trypsinized and plated at 1.5 x 10" (cucurbitacin E)
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and 1x10" (genistein) cells/well 24 hours before treatment. Cells grown on four well
chamber slides (Falcon) were used for digital imaging.
GROWTH INHIBITION ASSAYS
Cucurbitacin E and Genistein
Fresh media containing cucurbitacin E at concentrations of 28, 56, 113, 225, 450
nM and a control containing the vehicle (0.1% dimethylsufoxide) were added to the 96-
well plates and incubated for 1, 2, and 3 days.
Similarly, fresh media containing genistein at concentrations of 10, 25, 50, 100,
200, 400p.M and controls containing the vehicle (0.1, 0.2, or 0.4% DMSO for 10-
100p.M, 200p.Mand 400p.M,respectively)were added to the 96-well plate and
incubated for 1, 3, and 6 days.
After treatment cells were stained with Heochst 33342 (10p.g/ml) in phosphate
buffered saline (PBS) for 30 minutes, washed with PBS, and read on the FLxSOO (Bio-
Tek Instruments Inc.) fluorescent microplate reader and analyzed using KC Junior
software.
Soy Extracts
Four total methanol extracts of soy containing unknown concentrationsof genistein
were dissolved in DMSO at a concentration of 25 mg/ml. Fresh media containing each
extract at a final concentration of 250p.g/ml along with a control containing the vehicle
(1% DMSO), and a trial of 100p.M(27p.g/ml) genistein for comparison were added to a
96-wellplate (plated as before) and incubatedfor 3 days. The treated plates were then
analyzed in the same manner as above.
Measurement ofApoptosis
Twenty-four hours after plating, MCF-7 cells were treated in four-well chamber
slides with a control containing the vehicle and either 113 nM cucurbitacin E (incubated
1, 2, and 3 days), or 100p.Mgenistein (incubated 1, 3, and 6 days). After treatment,
slideswerefixedwith 3.7%buffered formaldehyde, washedwithPBS, stainedusingthe
APO-BrdU TUNEL Assay Kit according to manufacturer's instructions, and
immediately coverslippedwith Fluoromount G (Southern BiotechnologyAssociates Inc,
Birmingham,AL). The slides were analyzed using a Nikon Eclipse TE-300 inverted
microscopeequippedfor fluorescence digital ratiometric imaging (Fryer Co., Huntley,
IE). The imageswerecaptured usinga NikonSuperFluor40x oil immersion objective
and CoolSnap FX digital CCD camera (Photometries, Trenton, NJ), (495nm excitation,
520 nm emission) and storedfor analysis. Imaginganalysis was performed using
MetaMorph 5.0 software (Universal Imaging Corp.). Apoptotic indices were calculated
by counting numberof apoptotic cells, and the total numberof cells in 3-4 randomly
chosen fields of view.
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RESULTS
Cucurbitacin E
MCF-7 cells treated with cucurbitacin E exhibited dose dependant growth inhibition
(Figure 1A), supporting other groups (2) findings of growth inhibition on various
different carcinoma cell lines. We estimated an EC50of 100 nM after 3 days of
incubation (Figure IB). Under a light microscope morphological changes were also
evident in treated cells characteristic of necrotic cells (not shown).
TUNEL assay was performed to determine what percentages of cells were
undergoing apoptosis. Staining revealed only base line levels of apoptosis comparable to
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Figure 1. Growth Inhibition assay for MCF-7 cell treated with various concentrations
of cucurbitacin E for 1, 2, and 3 days.
Values are means ±SEM. (*), differs from the corresponding control, P<.05. (**), day 3 mean is
differentfrom day 1 mean in same treatmentgroup, P< .05. Growthwas measuredstaininglive cells
with DNA stain Hoechst 33342.
Genistein
MCF-7 cells treated with genistein exhibited a dose dependant growth inhibition
(Figure2A).Wefound an EC50 of 85p.M after 6 days of incubation (Figure2B).We also
observed growth stimulation at low concentrations (< 25p,M) of genistein.











Figure 2. Growth Inhibition assay for MCF-7 cell treated with various concentrations of
genistein for 1, 3, and 6 days.
Values are means ±SEM. All treatment group's means differ from control in day 6, P<.05. Growth
was measured staining live cells with the DNA stain Hoechst 33342.
Results from the TUNEL assay showed significant apoptosis present in the treated
wells after 3 and 6 days of incubation in comparison to the control (Table 1).
Morphological appearance (rounded appearance, cell shrinkage, nuclear blebbing) of
treated cells were charaeteristie of apoptosis, further supporting that apoptosis was




Day 3 Day 6 Day 3 Day 6
Apoptotic
index. %
< 1 < 1 13.6 + 3.1 29.3 + 9.5
Table 1. Genistein treatment induces apoptosis in MCF-7 cells.
Apoptotic cells were counted in 3-5 randomly chosen fields of view for each day and treatment.
Apoptotic indices were calculated by dividing the number of apoptotic cells by the total number of
cells; means ±SEM.
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Figure 3A-D. Apoptosis in MCF-7 cells induced by genistein treatment.
Immunofluorecence detectionof apoptosiswith theAPO-BrdUTUNELAssay Kit. (A) light image
of controlcells after 6 days of growth,(B) corresponding fluorescence imageof controlcells. (C)
Light image of cells treated with 100p.M genistein for6 days, (D)corresponding fluorescent image.
EFFECTS OF CUCURBITACIN E AND GENISTEIN IN MCF-7 55
Soy Extracts
Treatment with soy extract IV (250|JLg/ml) resulted in growth inhibition similar to








Con extract I extract II extract III extract IV GenlOO
Figure 4. Inhibition assay of four soy extracts compared to 100p.M treatment of genistein.
Extracts I, II, III and IV derived from soy of maturity groups 3 (CF46I), 4 (KS 4202), 4 (KS 5502N),
and 5 (MGS). Values are means ±SEM. (*), mean differed from control groups mean by P<.05.
DISCUSSION
When screening compounds for therapeutic potential against cancer, desirable
characteristics include growth inhibition at relatively low concentrations and specific
targeting of transformed cells leaving remaining tissue unharmed. One drawback of
many cancer therapies currently used is the inability of many effective drugs to do the
latter efficiently, leaving the patient to endure the harsh side effects. One method of
avoiding this would be to find a compound that can induce natural cell death through
apoptosis in transformed cells. Although cucurbitacin E's mechanism of growth
inhibition occurs under low (nanomolar) concentrations, our data indicates that it does
not target the apoptosis pathway. Therefore the compound's ability to differentiate
between normal and transformed cells is questionable, possible limiting its capability as
an anticancer agent.
Genistein induces growth inhibition, although higher concentrations (micromolar)
are needed to see the effect. This is supportive of results found by other groups (I, 4, 5)
on various carcinoma cell lines. In addition, genistein does appear to target the apoptosis
pathway (See Table 1) making it a much more appealing anticancer agent. The next step
56 EFFECTS OF CUCURBITACIN E ANDGENISTEIN IN MCF-7
in investigation of genistein will be to elucidate the mechanism of apoptosis and whether
this mechanism will result in targeting of transformed cells. Other characteristics of
genistein needed to be taken under considerationwhen consideringit as an anticancer
agent, include its estrogenic effects. Observedin this study and others (5, 7), low
concentrations of genistein stimulates cell growth. Hsieh et al. found that genistein at low
concentrations in fact could act as a weak estrogen, which may be associated with
increased risk of breast cancer. It has also been shown that in vivo this leads to mammary
gland differentiationin rats, which when administeredat a young (prepuberty) age
resulted in reduced incidence and multiplicity of breast tumors (2). Without a doubt,
finding the mechanismby which genistein affects mammary tissue will be a key to
understanding these diverse effects.
Treatment with the total methanol extracts of different soy maturity groups resulted
in a spectrum of growth inhibition.While some extracts did not show any growth
inhibition, extract IV showed significant inhibition comparable to that by 100 jxM
genistein (see Figure 4). Extract I showedmild effects of growth inhibition, but with
more variabilityresulting in an averagenot statistically significant from the control.
These results indicate that soy, grown under different environmental conditions may
contain differing amounts of genistein and other bioactive compounds. It also represents
yet anothervariable whenstudying howconsumption of soy leads to reducedincidences
of cancer.
In conclusion, our data clearly demonstrates that cucurbitacin E inhibits growth in a
dose-dependant manneron mammary carcinoma cells. Its mechanism appears due to its
high cytotoxicity and not the apoptosis pathway. Genisteinplainly induces apoptosis in
mammarycarcinomacells resultingin growthinhibition.The mechanismof apoptosisis
still to be elucidated and may be a target for anticancer therapy. Extracts of soy,
containingundetermined amountsof genistein, also show growthinhibitionat different
levels contingenton the geographical locationfrom which the soy was obtained.
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